ALKS vs OGN · P/E 14, rev $1.56B vs P/E 3.4, rev $6.40B
Alkermes Plc (ALKS) versus Organon & Co (OGN) — a side-by-side from cached financials, not a winner call.
Alkermes Plc (ALKS) is a drug manufacturers - specialty & generic company listed on US.
Organon & Co (OGN) is a drug manufacturers - general company listed on US.
Latest reported ALKS revenue for 2024-12-31 was $1.56B. Net income was $367.1M. Revenue was down 6.4% from 2023-12-31 to 2024-12-31. ALKS currently screens at market cap $4.78B and trailing P/E 13.8.
Latest reported OGN revenue for 2024-12-31 was $6.40B. Net income was $864.0M. Revenue was up 2.2% from 2023-12-31 to 2024-12-31. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
ALKS currently screens at market cap $4.78B and trailing P/E 13.8. OGN currently screens at market cap $2.52B and trailing P/E 3.4.
Not investment advice. Open the ALKS and OGN stock pages for the full models.
Not investment advice.